[go: up one dir, main page]

PE20030277A1 - Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa - Google Patents

Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Info

Publication number
PE20030277A1
PE20030277A1 PE2002000652A PE2002000652A PE20030277A1 PE 20030277 A1 PE20030277 A1 PE 20030277A1 PE 2002000652 A PE2002000652 A PE 2002000652A PE 2002000652 A PE2002000652 A PE 2002000652A PE 20030277 A1 PE20030277 A1 PE 20030277A1
Authority
PE
Peru
Prior art keywords
chromane
pharmaceutical composition
composition including
dopa
fluorophenil
Prior art date
Application number
PE2002000652A
Other languages
English (en)
Inventor
Christoph Seyfried
Herrmann Russ
Frank Weber
Gerd Bartoszyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20030277A1 publication Critical patent/PE20030277A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL USO DE (R/S)-(-/+)-2- [5--(4-FLUOROFENIL)-3-PIRIDILMETILAMINOMETIL]-CROMANO O DE UNA SAL FISIOLOGICAMENTE ACEPTABLE DEL MISMO PARA EL TRATAMIENTO DE TRASTORNOS DEL MOVIMIENTO EXTRAPIRAMIDAL, EFECTOS ADVERSOS DE LAS DROGAS ANTI-PARKINSONIANAS, ENFERMEDADE DE PARKINSON IDIOPATICA, SINDROMES DIQUINESICOS Y COREICOS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL PRINCIPIO ACTIVO MENCIONADO QUE PUEDE ESTAR EN FORMA DE CLORHIDRATO Y UNA DROGA ANTIPARKINSONIANA SELECCIONADA DE L-DOPA COMBINADA CON BENSERAZIDE, CARBIDOPA EN COMBINACION CON UNO O MAS EXCIPIENTES
PE2002000652A 2001-07-26 2002-07-24 Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa PE20030277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26

Publications (1)

Publication Number Publication Date
PE20030277A1 true PE20030277A1 (es) 2003-03-25

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000652A PE20030277A1 (es) 2001-07-26 2002-07-24 Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Country Status (23)

Country Link
US (1) US7872030B2 (es)
EP (1) EP1408964B1 (es)
JP (1) JP2004538289A (es)
KR (1) KR20040029325A (es)
CN (1) CN1292749C (es)
AR (1) AR037496A1 (es)
AT (1) ATE352302T1 (es)
AU (1) AU2002355170B2 (es)
BR (1) BR0211358A (es)
CA (1) CA2455621C (es)
CY (1) CY1107616T1 (es)
DE (1) DE60217870T2 (es)
DK (1) DK1408964T3 (es)
ES (1) ES2280602T3 (es)
HU (1) HUP0402092A3 (es)
MX (1) MXPA04000775A (es)
MY (1) MY134059A (es)
PE (1) PE20030277A1 (es)
PL (1) PL208258B1 (es)
PT (1) PT1408964E (es)
RU (1) RU2297833C2 (es)
SI (1) SI1408964T1 (es)
WO (1) WO2003009835A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
ES2644049T3 (es) 2007-01-31 2017-11-27 Bial - Portela & Ca., S.A. Régimen de dosificación para inhibidores de COMT
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
BRPI1014865B1 (pt) 2009-04-01 2020-03-17 Bial - Portela & C.A., S.A. Composição que compreende grânulos compreendendo 2,5- dicloro- 3- (5- (3,4- dihidróxi- 5- nitrofenil)- 1,2,4- oxadiazol- 3- il)- 4,6- dimetilpiridina 1- óxido e formulação farmacêutica
KR102173836B1 (ko) 2009-09-11 2020-11-05 아이오니스 파마수티컬즈, 인코포레이티드 헌팅틴 발현의 조절
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH07507058A (ja) 1992-03-11 1995-08-03 インターニューロン　ファーマシューティカルズ，インコーポレーテッド 大型の中性アミノ酸（ｌｎａａ）の血中濃度の食後変動の低減
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
WO1995020587A1 (en) * 1994-01-31 1995-08-03 Pfizer Inc. Neuroprotective chroman compounds
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
EP1123933A1 (en) * 1994-10-14 2001-08-16 MERCK PATENT GmbH 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
JP4108747B2 (ja) 1995-07-13 2008-06-25 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 治療薬としてのピペラジン誘導体
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
EP1061924A1 (en) 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
JP2002513001A (ja) 1998-04-29 2002-05-08 アメリカン・ホーム・プロダクツ・コーポレイション 抗精神病性のインドリル誘導体
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
PL208258B1 (pl) 2011-04-29
RU2004105844A (ru) 2005-05-10
PL367291A1 (en) 2005-02-21
PT1408964E (pt) 2007-05-31
WO2003009835A2 (en) 2003-02-06
SI1408964T1 (sl) 2007-06-30
BR0211358A (pt) 2004-09-21
EP1408964B1 (en) 2007-01-24
HUP0402092A2 (hu) 2005-02-28
AU2002355170B2 (en) 2007-06-07
AR037496A1 (es) 2004-11-17
RU2297833C2 (ru) 2007-04-27
DK1408964T3 (da) 2007-05-21
DE60217870T2 (de) 2007-11-15
JP2004538289A (ja) 2004-12-24
DE60217870D1 (de) 2007-03-15
HK1068793A1 (en) 2005-07-29
US7872030B2 (en) 2011-01-18
CA2455621C (en) 2010-11-16
HUP0402092A3 (en) 2010-06-28
MY134059A (en) 2007-11-30
EP1408964A2 (en) 2004-04-21
WO2003009835A3 (en) 2003-08-07
CN1292749C (zh) 2007-01-03
US20040171645A1 (en) 2004-09-02
ATE352302T1 (de) 2007-02-15
CY1107616T1 (el) 2013-03-13
KR20040029325A (ko) 2004-04-06
CA2455621A1 (en) 2003-02-06
ES2280602T3 (es) 2007-09-16
MXPA04000775A (es) 2004-04-20
CN1535150A (zh) 2004-10-06

Similar Documents

Publication Publication Date Title
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
DE602006017261D1 (de) Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
CL2009000380A1 (es) Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras.
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
UY27018A1 (es) Derivados de la pirimidina
AR029412A1 (es) Forma cristalina
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
EA200970022A1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
BR0306923A (pt) Composição farmacêutica para regeneração de tecidos hepáticos para tratamento de cirrose do fìgado uso de 5-(2-pirazinil) -4-metil-1,2-ditiol-3-tiona

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed